In a market in turmoil, pharmaceutical laboratories and consumer heavyweights are positioning themselves.
Small revolution in the pharmaceutical industry. In mid-November, the world’s first treatment from the microbiome was approved. The Australian health authority has given the green light to a faecal transplant, developed by Australian biotech Biomebank, to treat a serious bacterial infection of the gut (known as Clostridioides difficile). At the end of November, a drug from Rebiotix, acquired four years ago by the Swiss laboratory Ferring, obtained its approval in the United States to treat the same disease. In April, that of the American biotech Seres Therapeutics should be next. It will be marketed by the world number one in the food industry, Nestlé, its shareholder for six years, which should pay up to 525 million dollars to obtain the rights.
The microbiome refers to the thousands of species of bacteria, viruses, fungi and other microorganisms that inhabit our gut. Its state can be affected by our environment, our diet or…
This article is for subscribers only. You have 70% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for €0.99 for the first month
Already subscribed? Login